Why IMU is a multi multi bagger, page-22574

First 22574 Last

Share
Profile

Follow
DTLP

984 Posts.

233

18/04/24

06:57

Post #: 73397768
Share

Originally posted by Harry58: ↑

The last two weeks has certainly presented an emotional roller-coaster for many Imugene shareholders.
The majority in my view are optimistic that the science will deliver positive outcomes for cancer sufferers and ultimately financial reward.

The problem for many is their perception of timing ... this is a speculative stock that requires patient capital. And of course as the saying goes, speculation leads to expectation which (if not met) can result in frustration.

An understanding of time frames in clinical trials will assist in setting expectations.
The company however, does not assist in this regard when they state in the MAST trial announcements that "the trial commenced in May 2022 and is anticipated to run for approximately 24 months".
Any punter would correctly interpret this to mean that the trial will finish in May 2024.
But no, according to the clinical trial information the estimated trial completion date has always been recorded as 31st January 2025.

In the last fortnight shareholders have been treated to no less than 5 price sensitive announcements.

3/4/2024 - Imugene to present at 2024 Cholangialcarcinoma Conference
4/4/2024 - Oncolytic Virotherapy CF33 Patent granted in China.
8/4/2024 - Vaxinia and HER-vaxx featured at AACR annual meeting.
15/4/2024 - Bile Tract Cancer Study opens after MAST High Dose Trial clearance.
16/4/2024 - Imugene and Kincel Bio Announce Strategic Partnership

This exceeded my expectations but as is the case for many of our price sensitive announcements the SP suffered adding more pain, anguish and frustration for shareholders.

Clearly a reset of expectations is required ....
the Vaxinia MAST trial has just cleared the 5th dosing cohort in IT Monotherapy at 3x10^8 without any safety issues and is commencing an expansion study cohort of 10 patients in an unmet need of Bile Tract Cancer. And of course there is the forthcoming read-out of the Azer-cel confirmation trial due this quarter, not to mention the OnCARlytic combination trial that has commenced on the 11th March 2024.

The development and progress of clinical trials under the leadership of Leslie and her team has been amazing and deserves full recognition.

And finally I want to acknowledge the patients in our trials who are fighting this horrible disease that hopefully our virotherapies can deliver improved outcomes.

In another post I noted that in the announcement for Expansion into Bile Tract Cancer, the cancer indications for the cleared 5th Monotherapy IT cohort were reported as "thymic carcinoma, triple negative breast cancer and cholangiocarcinoma".

And in light of comments made by Rob from Brisbane aka Rock_Robster on the Colon Cancer Support Group who commenced his dosing regimen on the 19th March for liver cancer at St Vincents in Melbourne it would appear that he is in the 6th dosing cohort of 1x10^9.
Rob has recently completed his third scheduled treatment on day 21 of his first cycle and is doing well.

GLTAH - Go Team Imugene
.

Expand

Great post thanks Harry. In reference to Rob that's great he is doing well. His update the other day didn't sound so great and it has since been removed. Do you have comm's with him outside of the Colon Chat forum where that update was posted? I seriously hope he has pulled through that rough patch he described and is on his way to recovery. After his third dose at the higher dosage it will be pretty amazing to follow his progress. Fingers crossed for him and all patients on the trial.

IMU Price at posting: 8.3¢ Sentiment: Hold Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

PRS

Prospech finds dynamite heavy REE grades from historic core in Finland

PR1

Nanocap Pure Resources acquires Reedy Creek garnet project, WA

First 22574 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.002(4.35%)		Mkt cap ! $357.0M

Open	High	Low	Value	Volume
4.7¢	4.9¢	4.6¢	$977.7K	20.56M

Buyers (Bids)

No.	Vol.	Price($)
13	3232340	4.7¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	854027	4

View Market Depth

No.	Vol.	Price($)
13	3232340	0.047
21	4498330	0.046
33	7014309	0.045
37	6583493	0.044
30	3316810	0.043

Price($)	Vol.	No.
0.048	854027	4
0.049	3622300	15
0.050	6027470	18
0.051	2006954	12
0.052	2391989	13

Last trade - 16.10pm 11/11/2024 (20 minute delay)

IMU (ASX) Chart

Why IMU is a multi multi bagger, page-22574

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Prospech finds dynamite heavy REE grades from historic core in Finland

Nanocap Pure Resources acquires Reedy Creek garnet project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why IMU is a multi multi bagger, page-22574

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Prospech finds dynamite heavy REE grades from historic core in Finland

Nanocap Pure Resources acquires Reedy Creek garnet project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News